Cargando…

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date

Tuberculosis (TB) is the most deadly infectious disease globally. Although most individuals achieve a cure, a substantial portion develop multi-drug resistant TB which is exceedingly difficult to treat, and the number of effective agents is dwindling. Development of new anti-tubercular medications i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stancil, Stephani L, Mirzayev, Fuad, Abdel-Rahman, Susan M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253981/ https://www.ncbi.nlm.nih.gov/pubmed/34234413 http://dx.doi.org/10.2147/DDDT.S281639

Ejemplares similares

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date
por: Dorey-Stein, Zachariah L, et al.
Publicado: (2021)

Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies
por: Mota, Filipa, et al.
Publicado: (2022)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Effects of genotype and food on naltrexone exposure in adolescents
por: Stancil, Stephani L., et al.
Publicado: (2022)

The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Target to treatment: A charge to develop biomarkers of response and tolerability in child and adolescent psychiatry
por: Stancil, Stephani L., et al.
Publicado: (2022)

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
por: Bruning-Barry, Rebecca, et al.
Publicado: (2022)

Correction: The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Short and Efficient Synthesis of the Antituberculosis Agent Pretomanid from (R)-Glycidol
por: Lucas, Tobias, et al.
Publicado: (2023)

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management
por: D'Oronzo, Stella, et al.
Publicado: (2018)

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
por: Ambroso, Jeffrey L., et al.
Publicado: (2022)

Profile of nintedanib in the treatment of solid tumors: the evidence to date
por: Awasthi, Niranjan, et al.
Publicado: (2015)

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
por: Whitfield, Thomas, et al.
Publicado: (2016)

Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
por: Baptista, Rafael, et al.
Publicado: (2018)

Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid
por: Thompson, Andrew M., et al.
Publicado: (2017)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
por: Zou, Yuanxi, et al.
Publicado: (2022)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

Date Palm Tree (Phoenix dactylifera L.): Natural Products and Therapeutic Options
por: Al-Alawi, Reem A., et al.
Publicado: (2017)

Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer
por: Nguyen, Hanh Thuy, et al.
Publicado: (2023)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Potential biomarker of brain response to opioid antagonism in adolescents with eating disorders: a pilot study
por: Stancil, Stephani L., et al.
Publicado: (2023)

Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date
por: Kim, Jean, et al.
Publicado: (2020)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen, Eric R, et al.
Publicado: (2020)

Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence
por: Chen, Jia-Huang, et al.
Publicado: (2021)

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
por: Lyons, Michael A.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2kvfsn95nh9cc4i22i4125n66o